Patents by Inventor Shude Yan

Shude Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
    Patent number: 11525005
    Abstract: Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: December 13, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shude Yan, Jiahua Jiang, Qiyue Hu, Lianshan Zhang, Guoqing Cao, Xueming Qian, Fei Teng
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20220251240
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: February 3, 2022
    Publication date: August 11, 2022
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Shude Yan
  • ANTI-4-1BB ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
    Publication number: 20210363266
    Abstract: Provided are an anti-4-1BB antibody, an antigen-binding fragment thereof and medical use thereof. Further, provided are a chimeric antibody and a humanized antibody comprising a CDR region of the anti-4-1BB antibody, as well as a pharmaceutical composition comprising a human anti-4-1BB antibody or an antigen-binding fragments thereof, and use thereof as anti-cancer medicaments. In particular, provided is use of a humanized anti-4-1BB antibody in the preparation of a medicament for the treatment of diseases or conditions mediated by 4-1BB.
    Type: Application
    Filed: January 21, 2019
    Publication date: November 25, 2021
    Inventors: Hao HUANG, Jiahua JIANG, Shude YAN, Guoqing CAO, Lianshan ZHANG
  • ANTI-CD40 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
    Publication number: 20200148778
    Abstract: Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 14, 2020
    Inventors: Shude Yan, Jiahua Jiang, Qiyue Hu, Lianshan Zhang, Guoqing Cao, Xueming Qian, Fei Teng
  • ANTI-GITR ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF
    Publication number: 20200131263
    Abstract: Provided are an anti-GITR antibody, an antigen-binding fragment thereof, and pharmaceutical uses thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR of the anti-GITR antibody, a pharmaceutical composition containing the anti-GITR antibody or the antigen-binding fragment thereof, and use of the anti-GITR antibody in preparation of an anti-cancer drug. In particular, provided is a humanized anti-GITR antibody, and its use in the preparation of drugs for treating GITR-mediated diseases or disorders.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 30, 2020
    Inventors: Shude YAN, Jiahua JIANG, Hao HUANG, Lianshan ZHANG, Guoqing CAO
  • ANTI-CD27 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USE OF SAME
    Publication number: 20190225698
    Abstract: An anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use of the same are described. Further, provided are a chimeric antibody comprising a CDR of the anti-CD27 antibody, a humanized antibody, a pharmaceutical composition comprising a human anti-CD27 antibody or an antigen-binding fragment thereof, and use of the same as an anti-cancer drug. The present invention particularly relates to a human anti-CD27 antibody and use thereof in preparing a drug for treating a CD27-mediated disease or disorder.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 25, 2019
    Inventors: Shude YAN, Jiahua JIANG, Lianshan ZHANG, Guoqing CAO
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20180208680
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
  • Antibodies for botulinum neurotoxins
    Patent number: 9902781
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 27, 2018
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Shude Yan
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20160229921
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: December 11, 2015
    Publication date: August 11, 2016
    Inventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20150030600
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: August 31, 2011
    Publication date: January 29, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti